Pregnancy and congenital complete atrioventricular block: management during pregnancy and the periparturient period
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2018, Vol 3, Issue 6
Abstract
Complete atrioventricular block (AVB) is rare during pregnancy. Congenital atrioventricular block is the most common type of heart block in this group of patients. About one‐third of female patients with complete AVB remain asymptomatic until adulthood and may be first diagnosed during pregnancy. We present a case of a 31‐year‐old pregnant woman with complete AVB who was in her final stage of pregnancy. After reviewing the various advantages and disadvantages of feasible approaches with the patient, we decided to use fluoroscopy‐guided temporary backup pacemaker implantation. Estimated radiation skin dose was small and safe. The patient agreed to this treatment plan. Four days prior to scheduled cesarean delivery (39 weeks of gestation), during a one‐day stay in the hospital, the pa‐ tient underwent single‐chamber temporary pacemaker implantation (using transvenous active fixation lead and external re‐sterilized pacemaker). The abdominal and pelvic regions were covered with a lead shield. The caesarean delivery was uneventful and the baby was healthy with an Apgar score of 10. JRCD 2018; 3 (6): 204–208.
Authors and Affiliations
Andrzej Ząbek, Barbara Małecka, Paweł Tomasz Matusik, Maciej Dębski, Krzysztof Boczar, Jacek Lelakowski
Isolated right ventricular endomyocardial fibrosis in a young male with chronic myeloid leukemia (RCD code: III‑3F.2)
Endomyocardial fibrosis (EMF) is a rare disease of unknown etiology which is more prevalent in tropical countries. EMF is associated with fibrosis of endomyocardium, involving one or both ventricles. It usually presents...
Pulmonary arterial hypertension after systemic‑to‑pulmonary shunt correction (RCD code: II-1A.4d)
Pulmonary arterial hypertension develops in a significant number of patients with congenital heart diseases. Congenital heart diseases predispose to pulmonary vascular remodeling as a result of increased pulmonary blood...
The role of pharmacotherapy in the treatment of chronic thromboembolic pulmonary hypertension (RCD code: II-1A.5)
Chronic thromboembolic pulmonary hypertension (CTEPH) is a debilitating disease caused by chronic obstruction of major pulmonary arteries. The median age of patients at diagnosis of CTEPH is 63 years and both genders are...
Doxorubicin cardiomyopathy – case report and review of histopathologic findings (RCD code: III‐1B.5a)
The anthracycline anticancer drug Doxorubicin (Adriamycin) is an effective and frequently used chemotherapeutic agent for various malignancies. The use of doxorubicin is limited by its major adverse effect, cardiotoxicit...
Journal of Rare Cardiovascular Diseases: “One finger cannot lift a pebble” – cooperation as the only way to move forward
Dear Readers,Gaining more experience and exchange of knowledge in one thing is the only way to advance the field of rare cardiovascular diseases (RCD). Taking care of RCD patients on a daily basis quickly leads to realiz...